Related Experiment Video

Updated: Aug 8, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

[Non pharmacological interventions in dementia: a review and prospect]

Pascale Dorenlot1

  • 1Fondation Médéric Alzheimer, Pôle Etudes, Paris. dorenlot@med-alz.org

Psychologie & Neuropsychiatrie Du Vieillissement
|June 7, 2006
PubMed

Insights

Non-pharmacological interventions show promise for Alzheimer's disease and related disorders. Promising approaches include cognitive rehabilitation, reminiscence therapy, and behavioral therapies for caregivers and staff.

Area of Science:

  • Gerontology
  • Neuroscience
  • Psychiatry

Context:

  • Alzheimer's disease and related disorders (ADRD) present significant challenges.
  • Non-pharmacological interventions (NPIs) are increasingly researched for ADRD management.
  • Current evidence for NPI efficacy in ADRD is limited by trial size and intervention precision.

Purpose:

  • To review and highlight promising non-pharmacological interventions for Alzheimer's disease and related disorders.
  • To identify areas within NPIs that show the most reliable data and potential for future research.
  • To synthesize current findings on cognitive, emotional, behavioral, and environmental interventions.

Summary:

  • Individualized cognitive rehabilitation strategies show promise for cognitive interventions.
  • Reminiscence therapy is a promising emotion-oriented intervention.
  • Interventions for caregivers, especially those involving patient presence, yield reliable data.
  • Behavioral therapies for caregivers and staff demonstrate effectiveness in managing depression and challenging care situations.
  • Environmental and sensory stimulation techniques show potential for influencing mood and behavior in dementia patients.

Impact:

  • Identifies specific NPIs with the most reliable evidence for ADRD.
  • Highlights the need for more precise, evidence-based research in promising areas like environmental and sensory interventions.
  • Provides a foundation for developing and refining NPIs to improve quality of life for individuals with ADRD and their caregivers.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...